



REF: - SAROJA/NSE/2024

13.11.2024

To,

The Manager,
Listing Department,
The National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol : SAROJA

Dear Sir/Madam,

Sub: statement of deviation(s) or variation(s) under Regulation 32 SEBI (LODR) Regulations, 2015 for the half year ended 30th September, 2024.

Pursuant to the Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby confirms that there has been no deviation(s) or variation(s) in the use of the proceeds raised from the issue of 10,84,800 Equity Shares.

We further submit and state that the funds raised through the aforesaid issue has been utilized till as per enclosed statement till 30th September, 2024 and have been used for the purpose as stated in the objects of the issue in prospectus of the company, enclosing statement as required for the same .

We further inform that the said statement is reviewed by the Audit Committee in its meeting held on 13th November 2024.

We request you to kindly take note of this information on your record.

Thanking You,

Yours faithfully,

For Saroja Pharma Industries India Limited

Manish Dasharath Kamble
Whole-Time Director
DIN : 08330224



SAROJA PHARMA
INDUSTRIES INDIA LIMITED

+022 20810011

info@sarojapharma.com

www.sarojapharma.com

209, Ecstasy Business Park,
City of Joy Complex, JSD Road,
Mulund (W), Mumbai-400080.



**STATEMENT OF DEVIATION / VARIATION IN UTILISATION OF FUNDS RAISED THROUGH
PUBLIC ISSUE FOR THE QUARTER / HALF-YEAR ENDED ON 30TH SEPTEMBER 2024**

Name of Listed Entity	Saroja Pharma Industries India Limited
Mode of Fund Raising	Public Issue (Initial Public Offer)
Date of Raising Funds	31st August, 2023 to 05th September 2023 (Listed on 13th September, 2023 at NSE Emerge)
Amount Raised	Rs. 911.23 Lakhs
Report filed for Half Year ended	30 th September, 2024
Monitoring Agency	Not Applicable
Monitoring Agency Name, if Applicable	Not Applicable
Is there a Deviation/ Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of Shareholder Approval	Not Applicable
Explanation for the Deviation/ Variation	Not Applicable
Comments of the Audit Committee after review	-----
Comments of the auditors, if any	-----
Objects for which funds have been raised and where there has been a deviation, in the following table	There is no deviation

(INR IN LAKHS)

Original Object	Modified Object, if any	Original Allocation (Rs. in Lakhs)	Modified Allocation, if any	Funds Utilised	Amount of Deviation / Variation for Quarter according to applicable object	Remarks, if any
To Set-up a Manufacturing Unit	Not Applicable	704.88	-	399.98 Lakhs	Not Applicable	No deviations or variations.
To repay the Unsecured Loan of the Company	Not Applicable	175.00	-	175.00 Lakhs	Not Applicable	No deviations or variations.
Public Issue related expenses	Not Applicable	31.35	-	30.97 Lakhs	Not Applicable	No deviations or variations.

Deviation or variation could mean:

(a) Deviation in the objects or purpose for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

For Saroja Pharma Industries India Limited

Manish Dasharath Kamble
Whole - Time Director
DIN : 08330224



SAROJA PHARMA INDUSTRIES INDIA LIMITED | CIN NO : U24110MH2019PLC319508

Regd. Address :- 305, Kailash Tower, Shiv Shristi Complex, Goregaon Link Road, Mulund West, Mumbai-400080.